Chui Ping LEE

Dr. Chui Ping LEE

The Chinese University of Hong Kong School of Pharmacy
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2011 in The Journal of Sexual Medicine
Verified
Journal Article
Closed access
CNChi-Fai, Anthony Ng
Chi-Fai, Anthony Ng
CLChui Ping LEE
Chui Ping LEE
AHAllen Ho
Allen Ho
VLVivian WY Lee
Vivian WY Lee

14 March 2014 in Brain and Behavior
Verified
Journal Article
Open access
PDF file
WYWai‐Yin Yau
Wai‐Yin Yau
MCMan‐Chi Chan
Man‐Chi Chan
YWYun Kwok WING
Yun Kwok WING
HLHo‐Bun Lam
Ho‐Bun Lam
WLWei Lin
Wei Lin
CLChui Ping LEE
Chui Ping LEE
Background: Noncontinuous antidepressant use is frequently observed in clinical practice despite the standard recommendation of at least 6–9 months of continuous treatment. The problem may be more serious in Chinese populations where stigmatization is common. This retrospective cohort study investigated the rate of noncontinuous antidepressant use and subsequent rate of relapse and recurrence in psychiatric Chinese outpatients by examining the prescription records, electronic medical records, and written medical records. Factors associated with noncontinuous antidepressant use were also identified.Methods: We reviewed the medical records of 189 patients newly dispensed with an antidepressant in the psychiatric outpatient clinic during year 2006 and 2007. Primary outcome was the rate of noncontinuous antidepressant use within 6 months of therapy. Secondary outcomes included the factors associated with noncontinuous antidepressant use and the rate of subsequent depression relapse and recurrence within 1 year of starting treatment.Results: Among the 189 subjects included in this study, 46% were noncontinuous users of the newly prescribed antidepressant therapy. The noncontinuous users were found to have an eightfold increase (OR: 8.42, 95% CI: 3.30–21.47) in the risks of relapse/recurrence depressive episodes within 1 year after treatment initiation. Younger age (P = 0.008), female, (P = 0.029), residency in public housing estate (P = 0.029), experiencing side effects (P = 0.024), infrequent follow‐ups (P = 0.006), and earlier onset of diagnosis (P = 0.034) were factors significantly associated with noncontinuous antidepressant use.Conclusions: Noncontinuous antidepressant use is common in the local Chinese depressive patients and associated with a high rate of relapse and recurrence. Collaborative multidisciplinary approaches that target patient education and enhancement of follow‐up adherence are needed.

2 May 2018 in The Canadian Journal of Hospital Pharmacy
Verified
Journal Article
Open access
PDF file
CLChui Ping LEE
Chui Ping LEE
Health Care System and Pharmacy Practice in Hong Kong

10 February 2021 in JMIR Medical Informatics
Verified
Journal Article
Open access
KSKei Hong So
Kei Hong So
CTCheuk Wun Ting
Cheuk Wun Ting
CLChui Ping LEE
Chui Ping LEE
TLTai Ning Lam
Tai Ning Lam
SCSau Chu Chiang
Sau Chu Chiang
YCYin Ting Cheung
Yin Ting Cheung
Background: Innovation in technology and automation has been increasingly used to improve conventional medication management processes. In Hong Kong, the current practices of medication management in old age homes (OAHs) are time consuming, labor intensive, and error prone. To address this problem, we initiated an integrated medication management service combining information technology, automation technology, and the Internet of Things in a cluster network of OAHs. Objective: This pilot study aimed to evaluate the impact of the medication management program on (1) medication management efficiency, (2) medication safety, and (3) drug wastage in OAHs. We compared the time efficiency and the reductions in medication errors and medication wastage in OAHs before and at least 2 weeks after the implementation of the program. Methods: From November 2019 to February 2020, we recruited 2 OAHs (serving 178 residents) in Hong Kong into the prospective, pre-post interventional study. The interventional program consisted of electronic medication profiles, automated packaging, and electronic records of medication administration. Using 3-way analysis of variance, we compared the number of doses prepared and checked in 10-minute blocks before and after implementation. We received anonymous reports of medication errors from OAH staff and analyzed the results with the Fisher exact test. We also calculated the quantity and cost of wasted medications from drug disposal reports. Results: The number of doses prepared and checked in 10-minute blocks significantly increased postimplementation (pre: 41.3, SD 31.8; post: 70.6, SD 22.8; P<.001). There was also a significant reduction in medication errors (pre: 10/9504 doses, 0.1%; post: 0/5731 doses; P=.02). The total costs of wasted medications during January 2020 in OAH 1 (77 residents) and OAH 2 (101 residents) were HK $2566.03 (US $328.98) and HK $5249.48 (US $673.01), respectively. Conclusions: Our pilot study suggested that an innovative medication management program with information technology, automation technology, and Internet of Things components improved the time efficiency of medication preparation and medication safety for OAHs. It is a promising solution to address the current limitations in medication management in OAHs in Hong Kong.

JLJoyce Tik Sze Li
Joyce Tik Sze Li
CLChui Ping LEE
Chui Ping LEE
WTWai Kwong Tang
Wai Kwong Tang
Background: The COVID-19 pandemic has had substantial impacts on citizens’ daily living. Concerns over mental health issues are rising. Recent studies assessing the psychosocial impact of COVID-19 on the general public revealed alarming results. Meanwhile, the impact of the COVID-19 pandemic on mental health among patients with pre-existing psychiatric disorders remained unclear. Methods: Patients diagnosed with anxiety disorders, depressive disorders, bipolar disorders, or schizophrenia were invited to complete a survey between July and October 2020. The survey collected information on subjects’ demographics, accommodation status, changes in mental health status during the COVID-19 outbreak, and the factors that affect subjects’ mental health during COVID-19. The primary outcome of this study was the change in mental health, defined by psychiatric symptom change and patient satisfaction on symptom control. The secondary outcomes were patients’ emotional status—measured by the Depression, Anxiety and Stress Scale (DASS-21)—during the COVID-19 pandemic and factors that impacted patients’ mental health during the COVID-19 pandemic. Results: Out of the 294 patients recruited, 65.0% were living in hostel while 35.0% were living in the community. The proportion of patients with ‘unsatisfied’ or ‘very unsatisfied’ mental disease control increased from 10.2% to 17.1% after the COVID-19 outbreak (p < 0.001). Under the DASS-21 questionnaire, 24.2% subjects, 32.6% subjects, and 18.9% subjects were classified as severe or extremely severe in terms of the level of depression, anxiety, and stress they experienced, respectively. Patients living in the community, patients with mood disorders, and female patients reported significantly worse control over anxiety and mood symptoms. The three major factors that affected patients’ mental health during COVID-19 were ‘reduced social activities’, ‘worries over people around getting infected’, and ‘reduced exercise’. Conclusion: Psychiatric patients in general have poorer disease control after the COVID-19 outbreak. Patients in the community appeared to be more affected than patients residing in hostels. More efforts should be directed to screening patients with pre-existing mental health disorders to enable timely interventions.

31 January 2022 in JMIR Medical Informatics
Verified
Journal Article
Open access
KHKa Ho Matthew Hui
Ka Ho Matthew Hui
HLHugh Simon Lam
Hugh Simon Lam
CCCheuk Hin Twinny Chow
Cheuk Hin Twinny Chow
YLYuen Shun Janice Li
Yuen Shun Janice Li
PLPok Him Tom Leung
Pok Him Tom Leung
TLTai Ning Lam
Tai Ning Lam
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Intravenous (IV) vancomycin is used in the treatment of severe infection in neonates. However, its efficacy is compromised by elevated risks of acute kidney injury. The risk is even higher in neonates admitted to the neonatal intensive care unit (NICU) where pharmacokinetics of vancomycin vary widely among neonates. Therapeutic drug monitoring has been an integral part of vancomycin treatment to balance efficacy against toxicity. This involves individual dose adjustments based on observed serum vancomycin concentrations (Cs). However, the existing trough-based approach shows poor evidence for clinical benefits. The updated clinical practice guideline recommends population pharmacokinetic (popPK) model-based approaches, targeting area under curve preferably through the Bayesian approach. Since Bayesian methods cannot be performed manually and require specialized computer programs, there is a compelling need to provide the clinicians with a user-friendly interface to facilitate accurate, personalized dosing recommendations for vancomycin in critically ill neonates. Objective: Utilizing medical data from electronic health records (EHRs) to develop a popPK model and subsequently build a web-based interface to perform model-based individual dose optimization of IV vancomycin for NICU patients in local medical institutions. Methods: Medical data of subjects prescribed with IV vancomycin in the NICU of Prince of Wales Hospital and Queen Elizabeth Hospital in Hong Kong were extracted from EHR sources, namely Clinical Information System, In-Patient Medication Order Entry, and electronic Patient Record. Patient demographics, such as body weight (WT) and postmenstrual age (PMA), serum creatinine (SCr), vancomycin administration records and Cs were collected. The popPK model employed a two-compartment infusion model. Various covariate models were tested against WT, PMA, and SCr , and were evaluated for the best goodness-of-fit. A previously published web-based dosing interface was adapted to develop the interface in this study. Results: The final dataset consisted of EHR data extracted from 207 subjects, with a total of 689 Cs measurements. The final model chosen explains 82% of the variability in vancomycin clearance. All parameter estimates are within the bootstrapping confidence intervals. Predictive plots, residual plots, and visual predictive checks demonstrate good model predictability. Model approximations show that the model-based Bayesian approach consistently promotes the probability of target attainment (PTA) above 75%, while only half of the subjects can achieve PTA over 50% with the trough-based approach. The dosing interface was developed with the capability to optimize individual doses with the model-based empirical or Bayesian approach. Conclusions: Utilizing EHRs, a satisfactory popPK model has been verified and used to develop the web-based individual dose optimization interface. The interface is expected to improve treatment outcomes of IV vancomycin in the treatment of severe infections among critically ill neonates. This study provides the foundation for a cohort study to demonstrate the utility of the new approach compared with previous dosing methods.